Legal status in Belgium

Per-substance legal status for Belgium, from sourced statutes where available. Legal information, not legal advice; drug laws change, so confirm with the destination’s embassy or drug authority before you travel.

83 confirmed substances5 not individually verifiedLast updated October 8, 2026

Confirmed legal status

1P-LSD

Legal status: 1P-LSD is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is 1-propionyl-LSD with 1P-LSD given as its abbreviation. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The Belgian list reaches this lysergamide by naming it, not by treating it as a variant of lysergide; lysergide has its own separate entry in Annex II limb A and the two are different entries.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 1P-LSD is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the substance is a named national entry rather than an international scheduling import. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to 1P-LSD is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. A lawfully obtained 1P-LSD medicine is not a thing this dossier records anywhere. No route specific to 1P-LSD was found in this dossier and none has been invented for it.
Documentation: Carry no expectation that a document route exists for this one. Annex IV limb B names it as a controlled substance and the dossier records no authorised Belgian medicine containing it, so there is no lawful dispensing packaging and no prescriber letter to produce. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

1P-LSD in Belgium, full detail →

2-FDCK

Legal status: 2-FDCK is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is 2-fluorodeschloroketamine with 2-FDCK as its abbreviation. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its parent ketamine is listed separately in Annex IV limb B, so the two sit in different annexes and the placement of one says nothing about the other.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2-FDCK is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the entry sits in the second limb of Annex II, which is not the limb the traveller document rule excludes. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to 2-FDCK is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no authorised Belgian medicine containing this dissociative. No route specific to 2-FDCK was found in this dossier and none has been invented for it.
Documentation: Carry documents for the actual product rather than for the name. Annex II limb B names 2-FDCK and no authorised Belgian medicine containing it is recorded, so the document exception has no lawfully obtained medicine to attach to. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is 2-fluorodeschloroketamine with 2-FDCK as its abbreviation · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

2-FDCK in Belgium, full detail →

25I-NBOMe

Legal status: 25I-NBOMe is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is 25I-NBOMe. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is listed in its own right and not as a member of the 2C-X generic family in Annex IVA group 7, which is a separate route in the same decree.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 25I-NBOMe is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the entry sits in the first limb of Annex II, the limb Belgium reserves for its strictest handling. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to 25I-NBOMe is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. Nothing in the dossier records an authorised medicine containing this phenethylamine. No route specific to 25I-NBOMe was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that a prescription can be produced for this one. Annex II limb A is the limb excluded from the article 3(4)(4) exception, so even a foreign prescription would not open the document route. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is 25I-NBOMe · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

25I-NBOMe in Belgium, full detail →

2C-B

Legal status: 2C-B is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name 2C-B and no further text. Because the entry sits in limb B and not limb A, the Annex IIA exclusion in article 3(4)(4) of the Royal Decree does not bar the traveller exception for it. That exception remains subject to every other term of that provision and nothing here reads it more widely than that. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The dossier records expressly that 2C-B must not be confused with brolamfetamine, also called DOB: they are different entries and similarity of name is not control.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2C-B is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the entry is the bare name and carries none of the offence itself. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to 2C-B is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This dossier records no authorised Belgian medicine containing 2C-B. No route specific to 2C-B was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on the traveller exception for this substance. Its limb is the excluded one, and the dossier records no Belgian authorised product that could be lawfully obtained in the first place. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name 2C-B and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

2C-B in Belgium, full detail →

2C-E

Legal status: 2C-E is controlled in Belgium, but not by being named. It is reached by the generic definition in Annex IVA group 7, which prints a 2,5-dimethoxyphenethylamine core and a defined set of substituents, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records that the substitution particular to 2C-E falls inside the printed R4 set, which is why the family reaches it; nothing here rests on resemblance to 2C-B.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2C-E is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the substance is reached by a printed generic structure rather than by its own name. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 2C-E is reached through the generic family in Annex IVA group 7 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. The printed substituent set, and not any medicine route, is what this row establishes. No route specific to 2C-E was found in this dossier and none has been invented for it.
Documentation: Carry the structural reasoning rather than the label. The control here comes from the printed core and substituent set in Annex IVA group 7, so a product question turns on what the material actually is. The generic family at Annex IVA group 7 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 7, the 2C-X derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic definition in Annex IVA group 7, which prints a 2,5-dimethoxyphenethylamine core and a defined set of substituents · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

2C-E in Belgium, full detail →

2C-I

Legal status: 2C-I is controlled in Belgium, but not by being named. It is reached by the same generic definition in Annex IVA group 7, applied to the iodinated substitution, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records that the iodine substitution particular to 2C-I falls inside the printed R4 set of that family.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2C-I is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the iodinated member is inside the printed family rather than named on its own. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 2C-I is reached through the generic family in Annex IVA group 7 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. No named Annex entry exists for this compound, and no Belgian medicine is recorded for it. No route specific to 2C-I was found in this dossier and none has been invented for it.
Documentation: Carry the point that this is a family result. 2C-I is not printed as its own entry: the control comes from the group 7 structure with its iodine substituent inside the printed range. The generic family at Annex IVA group 7 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 7, the 2C-X derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the same generic definition in Annex IVA group 7, applied to the iodinated substitution · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

2C-I in Belgium, full detail →

2C-T-7

Legal status: 2C-T-7 is controlled in Belgium, but not by being named. It is reached by the generic definition in Annex IVA group 7, applied to the thioalkyl substitution, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records that the thioalkyl substitution particular to 2C-T-7 falls inside the printed R4 set, so the sulfur bearing member is reached by the same family as its oxygenated relatives.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 2C-T-7 is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the thioalkyl member is caught by the printed family definition and not by a separate name. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 2C-T-7 is reached through the generic family in Annex IVA group 7 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. There is no named entry for this compound and no medicine route recorded for it. No route specific to 2C-T-7 was found in this dossier and none has been invented for it.
Documentation: Carry the distinction between a named entry and a family result. Annex IVA group 7 reaches 2C-T-7 through its printed structure, so the analysis of the material is what settles the question. The generic family at Annex IVA group 7 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 7, the 2C-X derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic definition in Annex IVA group 7, applied to the thioalkyl substitution · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

2C-T-7 in Belgium, full detail →

3-MMC

Legal status: 3-MMC is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is 3-methylmethcathinone with 3-MMC as its abbreviation. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its parent cathinone is a separate entry in Annex II limb A, so the ring substituted derivative and the parent alkaloid are listed in different limbs.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 3-MMC is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the cathinone derivative is named in the second limb of Annex II in its own right. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to 3-MMC is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no authorised Belgian medicine containing this cathinone. No route specific to 3-MMC was found in this dossier and none has been invented for it.
Documentation: Carry documents for what the material is. 3-MMC is a named entry in Annex II limb B and no Belgian authorised medicine containing it is recorded, so nothing lawful exists to carry. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is 3-methylmethcathinone with 3-MMC as its abbreviation · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

3-MMC in Belgium, full detail →

4-AcO-DMT

Legal status: 4-AcO-DMT is controlled in Belgium, but not by being named. It is reached by the generic tryptamine definition in Annex IVA group 5, which prints an indol-3-yl ethanamine core and the substituents allowed at the 3 position, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records that the acetoxy substituent is one of the options printed in that family, which is the reason the compound is reached.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 4-AcO-DMT is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the acetylated tryptamine is caught by a printed generic core and substituent list. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 4-AcO-DMT is reached through the generic family in Annex IVA group 5 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. The dossier records no authorised Belgian medicine containing this tryptamine. No route specific to 4-AcO-DMT was found in this dossier and none has been invented for it.
Documentation: Carry the structural basis. The printed family in Annex IVA group 5 allows an acetoxy substituent, and that is what places 4-AcO-DMT inside it rather than any resemblance to psilocybin. The generic family at Annex IVA group 5 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 5, the tryptamine derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic tryptamine definition in Annex IVA group 5, which prints an indol-3-yl ethanamine core and the substituents allowed at the 3 position · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

4-AcO-DMT in Belgium, full detail →

4-HO-MET

Legal status: 4-HO-MET is controlled in Belgium, but not by being named. It is reached by the generic tryptamine definition in Annex IVA group 5, reached through the hydroxy substituent it prints, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records the hydroxy option as printed in the family, which is what brings this compound inside it.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 4-HO-MET is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the hydroxylated tryptamine falls inside the printed family rather than being named separately. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 4-HO-MET is reached through the generic family in Annex IVA group 5 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. No named entry and no Belgian medicine record exists for this tryptamine in the dossier. No route specific to 4-HO-MET was found in this dossier and none has been invented for it.
Documentation: Carry the reasoning rather than a schedule number. The hydroxy substituent printed in Annex IVA group 5 is what reaches 4-HO-MET, so the identity of the material decides the result. The generic family at Annex IVA group 5 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 5, the tryptamine derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic tryptamine definition in Annex IVA group 5, reached through the hydroxy substituent it prints · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

4-HO-MET in Belgium, full detail →

5-MeO-DMT (Bufo / Toad)

Legal status: 5-MeO-DMT is controlled in Belgium, but not by being named. It is reached by the generic tryptamine definition in Annex IVA group 5, reached through the methoxy substituent it prints, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. Its unsubstituted relative dimethyltryptamine has a separate named entry in Annex II limb A, so the two are reached by different routes in the same decree.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 5-MeO-DMT is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the methoxylated tryptamine is reached by a printed family while its parent is separately named. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 5-MeO-DMT is reached through the generic family in Annex IVA group 5 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. Neither this compound nor its separately named parent has an authorised Belgian medicine on record. No route specific to 5-MeO-DMT was found in this dossier and none has been invented for it.
Documentation: Carry the difference between the two routes. The parent is a named Annex II entry while 5-MeO-DMT is a family result under Annex IVA group 5, and the family result depends on the printed substituent set. The generic family at Annex IVA group 5 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 5, the tryptamine derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic tryptamine definition in Annex IVA group 5, reached through the methoxy substituent it prints · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

5-MeO-DMT (Bufo / Toad) in Belgium, full detail →

6-APB

Legal status: 6-APB is controlled in Belgium, but not by being named. It is reached by the generic definition in Annex IVA group 1, which prints a 1-phenylpropan-2-amine core for the amphetamine derivatives, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. The dossier records expressly that the benzofuran structure sits within the printed core and substituent definition, and that no resemblance only inference was used.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to 6-APB is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the benzofuran amphetamine is reached by the printed amphetamine family core. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 6-APB is reached through the generic family in Annex IVA group 1 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. There is no named entry for this compound and no Belgian medicine record for it. No route specific to 6-APB was found in this dossier and none has been invented for it.
Documentation: Carry the structural finding. Annex IVA group 1 prints the phenylpropan-2-amine core, and the benzofuran ring system of 6-APB is inside the printed definition rather than merely similar to it. The generic family at Annex IVA group 1 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 1, the amphetamine derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic definition in Annex IVA group 1, which prints a 1-phenylpropan-2-amine core for the amphetamine derivatives · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

6-APB in Belgium, full detail →

7-Hydroxymitragynine (7-OH)

Legal status: 7-hydroxymitragynine is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry at all: Annex IV limb B names mitragynine and Annex IV limb C controls kratom plant material containing mitragynine, and neither names the 7-hydroxy metabolite. This is the sharpest trap in the Belgian table. The metabolite is not the printed entry, and Annex IVA carries no generic indole alkaloid or mitragynine derivative family that could reach it. Kratom material that contains the named mitragynine stays controlled through that content, so the isolated compound and the plant material give different answers. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and 7-hydroxymitragynine is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: this is a positive absence recorded after the named lists, the eight generic families and the plant material entries were all checked, not a failure to look. Where a material described by this name in fact contains a listed substance, article 2(14) reaches it as a preparation and the article 2bis ladder then applies to that content.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. 7-hydroxymitragynine is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. The compound has no Belgian annex placement of its own, and its parent alkaloid's placement does not travel to it. No route specific to 7-hydroxymitragynine was found in this dossier and none has been invented for it.
Documentation: Carry the distinction between the isolate and the plant. Kratom material containing mitragynine is controlled through Annex IV limb C, so material described as 7-hydroxymitragynine can still be controlled by what it actually contains. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for 7-hydroxymitragynine with the result that there is no entry at all: Annex IV limb B names mitragynine and Annex IV limb C controls kratom plant material containing mitragynine, and neither names the 7-hydroxy metabolite · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

7-Hydroxymitragynine (7-OH) in Belgium, full detail →

Adderall

Legal status: Adderall has no entry of its own in the Belgian lists and is controlled through what it contains. The basis relied on is the amphetamine entry printed in the annex, reached because the mixed amphetamine salts in the product are a preparation under article 2(14) of the decree, which defines a preparation as any solid or liquid mixture containing one or more substances, so the placement that matters is Annex II limb B, where AMFETAMINE is printed. The brand name is not the control. The decree reaches the product through its contents, and this row records the AMFETAMINE entry in the second limb of Annex II. Because the entry sits in limb B and not limb A, the Annex IIA exclusion in article 3(4)(4) of the Royal Decree does not bar the traveller exception for it. That exception remains subject to every other term of that provision and nothing here reads it more widely than that. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The operative provisions come from the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to Adderall is the article 2bis ladder in the Law of 24 February 1921, reached because the product is reached as a preparation containing a listed substance, under article 2(14) and because article 61 of the decree routes the breach there. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to Adderall is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This row records the amphetamine entry in the excluded limb, so the exception does not open on this row's own finding. No route specific to Adderall was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging if a stimulant of this kind is prescribed to you, and understand that on this row's placement the article 3(4)(4) exception is closed. A brand name on a box is not a Belgian classification. The placement relied on at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the amphetamine entry printed in the annex, reached because the mixed amphetamine salts in the product are a preparation under article 2(14) of the decree, which defines a preparation as any solid or liquid mixture containing one or more substances · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Adderall in Belgium, full detail →

Alcohol

Legal status: Alcohol is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: a search of Annexes I to V and all eight Annex IVA families for alcohol and ethanol returned nothing, and the separate Belgian rules on alcoholic drinks do not classify it as a narcotic or a psychotropic. The second route was examined and it produced no drug classification: Belgium regulates alcoholic drinks through its own product rules, which are a different regime from the drug decree. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and alcohol is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the drug decree is simply not the instrument that governs this one. The consequences that do attach in Belgium come from the product regimes named in this row, and this table does not set them out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Alcohol is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no schedule placement to attach to the traveller rule for this substance. No route specific to alcohol was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that this row speaks to age limits, licensing, driving or duty. It records only that alcohol is absent from the drug annexes, and the dossier states that absence under other Belgian product, food, tobacco, alcohol, medicines or chemical law was not audited. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for alcohol with the result that there is no entry: a search of Annexes I to V and all eight Annex IVA families for alcohol and ethanol returned nothing, and the separate Belgian rules on alcoholic drinks do not classify it as a narcotic or a psychotropic · read at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Alcohol in Belgium, full detail →

Amphetamine

Legal status: Amphetamine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name amphetamine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its derivatives are handled separately: the printed generic family in Annex IVA group 1 reaches structures built on the phenylpropan-2-amine core, while this entry reaches the parent by name.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to amphetamine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the parent stimulant is named in the second limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to amphetamine is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The amphetamine row records the second limb of Annex II, which article 3(4)(4) does not exclude. No route specific to amphetamine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging where a stimulant containing amphetamine is prescribed, with a prescriber letter and the treatment period stated, and expect the quantity to be held to the three month limit. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name amphetamine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Amphetamine in Belgium, full detail →

Ayahuasca

Legal status: Ayahuasca has no entry of its own in the Belgian lists and is controlled through what it contains. The basis relied on is the dimethyltryptamine entry in the first limb of Annex II, reached because article 2(14) defines a preparation as a solution or mixture in any physical state containing one or more substances, so a brew carrying that substance is itself a preparation, so the placement that matters is Annex II limb A. Neither the name ayahuasca nor the plants used to make it are Annex entries. A brew is controlled because of what is dissolved in it, which means a preparation analysis and not a name decides the result. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The operative provisions come from the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to ayahuasca is the article 2bis ladder in the Law of 24 February 1921, reached because the liquid is reached as a preparation containing a first limb substance and because article 61 of the decree routes the breach there. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to ayahuasca is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. The substance the brew is controlled through sits in the excluded limb, so the document exception does not open for it. No route specific to ayahuasca was found in this dossier and none has been invented for it.
Documentation: Carry no religious or ceremonial exemption into Belgium on the strength of this row. The dossier records none, and the preparation definition in article 2(14) reaches a liquid by its contents. The placement relied on at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the dimethyltryptamine entry in the first limb of Annex II, reached because article 2(14) defines a preparation as a solution or mixture in any physical state containing one or more substances, so a brew carrying that substance is itself a preparation · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Ayahuasca in Belgium, full detail →

Barbiturates

Legal status: Controlled in Belgium member by member, and Belgium's own annexes name the members, so this is a finding rather than a deferral. The member by member check was run against the Belgian schedule and not merely against the substances this table happens to carry, and it returned twelve printed names. That distinction decides the cell: no barbiturate row exists in this table, but a list that names individuals is not silent merely because the table is. The Royal Decree of 6 September 2017 prints allobarbital, amobarbital, barbital, butalbital, butobarbital, cyclobarbital, methylphenobarbital, pentobarbital, phenobarbital, secbutabarbital and vinylbital in Annex III, and places secobarbital separately in Annex II. Those eleven Annex III entries and the separate Annex II entry were read from the annex text. So the specific barbiturate must be identified before any answer is given, and that is the finding. Which annex applies differs between them, because Annex II and Annex III are not the same limb and do not carry the same consequences, so naming the product is the whole of the question.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. Beyond that this cell cannot state the exposure, because the exposure is member specific and no member is resolved here. A controlled barbiturate reaches article 2bis of the Law of 24 February 1921 through article 61 of the decree. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. That ladder is set out as the one a proved member would meet, not as a finding about the class, and which member is in front of you is the question this cell cannot answer.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. There is no single placement to attach, because the class has no entry of its own and this table carries no member row. The eleven Annex III barbiturates are not in the excluded limb, so the document exception could apply to a lawfully obtained supply of one of them, while secobarbital sits in Annex II and its limb has to be read before the same conclusion is drawn. Which of those two answers applies is exactly what was not established here. No route specific to the class was found in this dossier and none has been invented for it.
Documentation: Carry no document on the strength of the class name, because this cell resolves no member and the members do not share one answer. Whatever you are carrying has to be identified by its own printed name before anything can be said about it: the eleven Annex III members and the separately placed Annex II secobarbital entry sit in different limbs, and the limb is what decides the traveller document question. Both were read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III and the separately placed Annex II entry, with articles 2, 8 and 61 and article 2bis of the Law of 24 February 1921 behind them, read for the individual barbiturates rather than for the class name · the eleven Annex III members and the separate Annex II secobarbital entry are what this citation supports, and no member row exists in this table to resolve the class against, which is why the status defers · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026 · Updated September 20, 2026

Barbiturates in Belgium, full detail →

Benzodiazepines

Legal status: Controlled in Belgium member by member rather than as a class, and this table resolves every member it carries. The decree has no class wide benzodiazepine entry: it prints individual names in Annex III. The members that also appear elsewhere in this table are alprazolam, clonazepam, diazepam, etizolam, lorazepam and nimetazepam, each named there in its own right, and the annex names further members that this table carries no row for, including bromazepam and midazolam. The specific benzodiazepine must be identified before any answer is given. A member without a row here is still a named member of the Belgian schedule, and the absence of a row is a fact about this table rather than about Belgium. Flunitrazepam is placed separately in Annex II, and non benzodiazepine hypnotics such as zolpidem are separate entries again rather than members of this class. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Each member is resolved by its printed entry and the class name resolves nothing.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. The exposure is member specific. A controlled member reaches article 2bis of the Law of 24 February 1921 through article 61 of the decree, and since the members in this table sit in Annex III while flunitrazepam sits in Annex II, the limb of the member actually proved is what controls the route. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement to attach is the member's. The six members resolved in this table are all in Annex III, which article 3(4)(4) does not exclude, so a patient carrying a lawfully obtained supply of one of them within the three month personal use limit is inside the exception rather than outside it. No route specific to the class was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging naming the specific benzodiazepine, not the class, with a prescriber letter stating the dose and the treatment period and the supply held to three months or less. Annex III and the separate Annex II entry were read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III with the separately placed Annex II entry, and articles 2, 8 and 61, read for the individual members of the benzodiazepines class rather than for the class name, with article 2bis of the Law of 24 February 1921 carrying the penalties · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026 · Updated September 20, 2026

Benzodiazepines in Belgium, full detail →

Buprenorphine

Legal status: Buprenorphine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name buprenorphine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is listed in the second limb of Annex II rather than with the Annex I opioids, so a placement guessed from its pharmacology would have put it in the wrong annex.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to buprenorphine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here this opioid partial agonist is named in the second limb of Annex II rather than in Annex I. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to buprenorphine is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Buprenorphine is a substitution treatment medicine in ordinary clinical use, which is squarely the situation article 3(4)(4) was written for. No route specific to buprenorphine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber letter stating the substitution treatment, the daily dose and the period covered, and keep the supply within three months of treatment. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name buprenorphine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Buprenorphine in Belgium, full detail →

Caffeine

Legal status: Caffeine is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: a search of Annexes I to V and all eight Annex IVA families for caffeine returned nothing, and the separate Belgian food and labelling rules for caffeinated products do not classify it as a narcotic or a psychotropic. The second route examined was the food and labelling regime, which is a product regime and produces no drug classification at all. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and caffeine is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the decree is silent because caffeine was never within its subject matter. The consequences that do attach in Belgium come from the product regimes named in this row, and this table does not set them out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Caffeine is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no annex placement at all, and the food and labelling rules that do apply are product rules rather than carriage rules. No route specific to caffeine was found in this dossier and none has been invented for it.
Documentation: Carry no inference from this row about labelling thresholds, energy drink rules or food supplement limits. It records only the absence from the drug annexes, and the dossier states the other regimes were not audited. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for caffeine with the result that there is no entry: a search of Annexes I to V and all eight Annex IVA families for caffeine returned nothing, and the separate Belgian food and labelling rules for caffeinated products do not classify it as a narcotic or a psychotropic · read at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Caffeine in Belgium, full detail →

Cannabinol

Legal status: Cannabinol is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: cannabinol is not a named entry, and Annex IVA group 4 prints indole, indazole, benzodiazole and pyrrole synthetic cannabinoid cores, none of which is the dibenzopyran core cannabinol has. The dossier states this one plainly: cannabinol is not tetrahydrocannabinol, and the named tetrahydrocannabinol entry is not a spelling based catch all that swallows every cannabinoid whose name resembles it. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and cannabinol is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the structural test was applied and failed, which is a finding rather than an oversight. Where a material described by this name in fact contains a listed substance, article 2(14) reaches it as a preparation and the article 2bis ladder then applies to that content.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Cannabinol is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no placement here, because the compound is outside the named list and outside the printed generic family. No route specific to cannabinol was found in this dossier and none has been invented for it.
Documentation: Carry the structural point with you. A product sold as cannabinol can still contain controlled tetrahydrocannabinol isomers, and the preparation definition would then reach it through that content rather than through this row. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for cannabinol with the result that there is no entry: cannabinol is not a named entry, and Annex IVA group 4 prints indole, indazole, benzodiazole and pyrrole synthetic cannabinoid cores, none of which is the dibenzopyran core cannabinol has · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Cannabinol in Belgium, full detail →

Cannabis / THC

Legal status: Cannabis is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is one covering cannabis and cannabis resin, extracts and tinctures above the printed combined threshold of 0.3 per cent delta-9-tetrahydrocannabinol plus its acid form. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The threshold is part of the entry, so the printed 0.3 per cent combined figure is what separates controlled material from material outside the entry, and no other number does that work.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to cannabis is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here personal possession by an adult has its own lower route under article 2ter and the special treatment recorded in the dossier, which does not erase the article 2bis exposure for aggravated supply conduct. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to cannabis is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no general medical cannabis dispensing route for a traveller and this row does not create one. No route specific to cannabis was found in this dossier and none has been invented for it.
Documentation: Carry the threshold in mind rather than a product claim. The entry turns on a combined 0.3 per cent figure, and a label asserting low content is not an analysis. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is one covering cannabis and cannabis resin, extracts and tinctures above the printed combined threshold of 0.3 per cent delta-9-tetrahydrocannabinol plus its acid form · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Cannabis / THC in Belgium, full detail →

Cathinone

Legal status: Cathinone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is the name cathinone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The parent alkaloid is listed here while the plant it comes from, khat, has its own separate entry in Annex IV limb C keyed to the presence of this same substance.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to cathinone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the parent alkaloid is named in the first limb of Annex II and the plant is listed separately. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to cathinone is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. No authorised Belgian medicine containing this alkaloid is recorded either. No route specific to cathinone was found in this dossier and none has been invented for it.
Documentation: Carry no expectation of a document route for this alkaloid. The limb is excluded and the dossier records no authorised Belgian medicine containing it. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name cathinone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Cathinone in Belgium, full detail →

CBD

Legal status: CBD (cannabidiol) is not a named controlled drug in Belgium, and the position that applies to it is a medicines or product one. The check found no controlled drug entry; the position recorded is a medicines and product one, with the AFMPS stating that a cannabidiol medicine received an authorisation in 2019 but is not currently marketed in Belgium, and that pharmacists may dispense magistral preparations made from pharmaceutical grade cannabidiol where the rules are met. This is a product and medicines position rather than a schedule placement, and the dossier records that other approved food, cosmetic and industrial hemp products may also be lawful. The controlled drug lists in the Royal Decree of 6 September 2017 do not reach it, and under the delegated model a substance outside the list the King has settled is not governed by article 2bis of the Law of 24 February 1921 at all. That is a statement about the drug decree only, and it does not make the substance unregulated.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and CBD (cannabidiol) is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. Here the drug decree does not supply the rule here; the medicines and product regimes do. Supplying a prescription only medicine outside the medicines rules remains an offence under those rules, which this row does not set out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. CBD (cannabidiol) is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. The magistral preparation route the AFMPS describes is a Belgian dispensing route inside Belgium, and it is not the traveller document exception. No route specific to CBD (cannabidiol) was found in this dossier and none has been invented for it.
Documentation: Carry the pharmacy documentation for a magistral preparation if one was dispensed to you, and do not treat a shop bought oil as the same thing. The authorised medicine is recorded as not currently marketed in Belgium. The medicines position was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for CBD (cannabidiol) with the result that there is no controlled drug entry · the position recorded is a medicines and product one, with the AFMPS stating that a cannabidiol medicine received an authorisation in 2019 but is not currently marketed in Belgium, and that pharmacists may dispense magistral preparations made from pharmaceutical grade cannabidiol where the rules are met · read at https://www.afmps.be/fr/medicaments_et_autres_produits_a_base_de_cannabis_ou_cannabidiol on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

CBD in Belgium, full detail →

Clonazepam

Legal status: Clonazepam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name clonazepam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is another individually named Annex III benzodiazepine, and its presence there is what the benzodiazepines row in this table resolves to for this member.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to clonazepam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here this antiepileptic benzodiazepine is named in the third annex. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to clonazepam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Clonazepam is prescribed for epilepsy, so an ordinary dispensed supply is the case the document rule contemplates. No route specific to clonazepam was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber letter naming the indication, the dose and the treatment period, and hold the quantity to no more than three months of treatment. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name clonazepam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Clonazepam in Belgium, full detail →

Cocaine

Legal status: Cocaine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name cocaine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The base form sold as crack is not a separate entry: it resolves to this same one, which is why the crack row in this table points here.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to cocaine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the alkaloid is named in the first limb of Annex I, the limb Belgium uses for the classic narcotics. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to cocaine is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. A lawfully obtained cocaine medicine for personal carriage is not something this dossier records, so the exception has little to attach to in practice. No route specific to cocaine was found in this dossier and none has been invented for it.
Documentation: Carry no expectation that the document exception will be of any practical use here. The limb is not excluded, but there is no ordinary dispensed cocaine medicine for a traveller to hold a prescription for. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name cocaine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Cocaine in Belgium, full detail →

Codeine

Legal status: Codeine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb B, where the entry is the name codeine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It sits in the second limb of Annex I rather than the first, which is the limb Belgium uses for the opioids it handles less strictly, and that limb distinction is part of the finding.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to codeine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the second limb of Annex I. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb B is the opioid limb Belgium handles less strictly than limb A, and that difference bears on the traveller document rule rather than on the band, which is the same for every listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to codeine is Annex I limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Codeine is widely dispensed as a medicine, so this is the ordinary case the rule contemplates. No route specific to codeine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging where codeine was prescribed, with a prescriber letter stating the dose and the treatment period, and keep the supply inside three months of treatment. The placement at Annex I limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name codeine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Codeine in Belgium, full detail →

Crack Cocaine

Legal status: Crack cocaine has no entry of its own in the Belgian lists and is controlled through what it contains. The basis relied on is the cocaine entry itself, because crack is cocaine in base form, with article 2(14) additionally reaching a mixture containing one or more listed substances, so the placement that matters is Annex I limb A. Crack is cocaine in base form and not a second Belgian schedule entry. Two routes reach it, the named compound and the preparation definition, and neither depends on the street name. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The operative provisions come from the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to crack cocaine is the article 2bis ladder in the Law of 24 February 1921, reached because the material is reached as the named alkaloid and, where it is a mixture, as a preparation as well and because article 61 of the decree routes the breach there. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to crack cocaine is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. There is no separate placement for the base form, so the placement is the one that attaches to cocaine. No route specific to crack cocaine was found in this dossier and none has been invented for it.
Documentation: Carry no belief that a different street form creates a different Belgian classification. The base form resolves to the same named entry. The placement relied on at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the cocaine entry itself, because crack is cocaine in base form, with article 2(14) additionally reaching a mixture containing one or more listed substances · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Crack Cocaine in Belgium, full detail →

Delta-8-THC

Legal status: Delta-8-THC is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is the tetrahydrocannabinol entry, printed with its listed isomers carrying the specified pentyl side chain. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The isomer list and the printed side chain are what do the work: the entry reaches listed isomers rather than anything that carries the letters in the name.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to Delta-8-THC is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the isomer is inside a named entry that is defined by its printed isomer list and side chain. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to Delta-8-THC is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This entry sits in the excluded limb, so the document exception does not open for it. No route specific to Delta-8-THC was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that a product marketed as a milder isomer is outside the entry. The annex prints the isomers it covers, and a marketing description is not an analysis. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the tetrahydrocannabinol entry, printed with its listed isomers carrying the specified pentyl side chain · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Delta-8-THC in Belgium, full detail →

Diazepam

Legal status: Diazepam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name diazepam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. This is the row that most needs saying plainly: diazepam is an Annex III substance in Belgium, not a narcotic in the first limb of Annex I, and nothing in the Belgian scheme attaches a twenty year exposure to a patient carrying a prescribed supply of it.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to diazepam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the third annex placement is the one most often mistaken for a narcotic placement, which is what produces the twenty year figure in accounts of this substance. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to diazepam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Diazepam is among the most commonly prescribed medicines in its class. No route specific to diazepam was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging, with a prescriber letter naming the patient, the dose and the treatment period, and keep the amount to no more than three months of treatment. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name diazepam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Diazepam in Belgium, full detail →

DMT

Legal status: DMT is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is dimethyltryptamine with DMT given as its abbreviation. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The same entry is what a brew such as ayahuasca is controlled through, by way of the preparation definition in article 2(14), so the compound and the liquid share one placement.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to DMT is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the tryptamine is named in the first limb of Annex II and reaches preparations containing it. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to DMT is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This entry is in the excluded limb, so the exception does not open for it. No route specific to DMT was found in this dossier and none has been invented for it.
Documentation: Carry no expectation of a document route. The limb is excluded, and the dossier records no Belgian authorised medicine containing this tryptamine. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is dimethyltryptamine with DMT given as its abbreviation · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

DMT in Belgium, full detail →

DOM

Legal status: DOM is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is one that pairs the older designation STP with DOM in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The dossier warns separately that 2C-B must not be confused with brolamfetamine, which is also called DOB; that is a different compound again and this entry does not reach it.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to DOM is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the substituted amphetamine is named in the first limb of Annex II under two designations. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to DOM is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. That is the excluded limb, so nothing in this row opens a carriage route. No route specific to DOM was found in this dossier and none has been invented for it.
Documentation: Carry the point that the annex uses an older designation for this compound. A search on one name alone can miss an entry that is printed under the other. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is one that pairs the older designation STP with DOM in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

DOM in Belgium, full detail →

DXM

Legal status: DXM (dextromethorphan) is not reached by the Belgian controlled drug lists on the text checked here. The search found an express exclusion rather than an entry: the morphinan extension printed in the first limb of Annex I carries the words excepting dextromethorphan and its salts. This is the rare case where the annex says so itself. The decree considered the compound and wrote it out of the extension, so the absence is textual rather than inferred from a search returning nothing. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and DXM (dextromethorphan) is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the exclusion is printed in the entry, which is the strongest form this finding can take. Where a material described by this name in fact contains a listed substance, article 2(14) reaches it as a preparation and the article 2bis ladder then applies to that content.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. DXM (dextromethorphan) is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no placement, because the printed entry excludes the substance rather than including it. No route specific to DXM (dextromethorphan) was found in this dossier and none has been invented for it.
Documentation: Carry the cough medicine in its original packaging as you would any other, and read this row as being about the drug decree only. The dossier does not audit the medicines regime for particular products. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for DXM (dextromethorphan) with the result that there is an express exclusion rather than an entry: the morphinan extension printed in the first limb of Annex I carries the words excepting dextromethorphan and its salts · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

DXM in Belgium, full detail →

Ephedrine

Legal status: Ephedrine is controlled in Belgium as a drug precursor rather than under Annexes I to IV of the Royal Decree of 6 September 2017. It is a category 1 scheduled substance in Annex I to Regulation (EC) No 273/2004 as amended, which applies in Belgium as EU law, and medicinal products containing ephedrine are addressed separately by the precursor framework and by the Belgian medicines rules. That is a different instrument from the delegated controlled drug list, and the difference matters: Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The precursor route regulates trade, record keeping and reporting rather than placing the substance on the narcotic or psychotropic annexes.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. No ceiling under article 2bis of the Law of 24 February 1921 is assigned from the EU precursor entry alone. The applicable Belgian precursor offence and the actual product facts would have to be identified first, and this row does not identify them. A category 1 listing is a controls and licensing regime for trade in a scheduled chemical, and reading a twenty year drug ceiling straight off it would be an error of instrument. Where a particular consignment or preparation turns out to engage the controlled drug annexes instead, that would be a different finding from this one and would carry its own route.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Ephedrine is not in Annexes I to IV at all, so there is nothing here for the exception to except, and a traveller question about an ephedrine containing medicine is a medicines and precursor question rather than a controlled drug one. The precursor framework addresses medicinal products containing ephedrine separately, and that is a supply chain rule rather than a patient carriage rule. No route specific to ephedrine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging for any ephedrine containing medicine, and treat quantities beyond personal treatment as a precursor question rather than a drug schedule one. The category 1 listing in Annex I to Regulation (EC) No 273/2004 as amended was read on 18 September 2026. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Regulation (EC) No 273/2004 as amended, Annex I category 1, the drug precursor route rather than the controlled drug annexes, with the Belgian precursor and medicines rules addressing medicinal products containing ephedrine separately · read at https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004R0273-20210113 on 18 September 2026 · the Belgian controlled drug instrument checked and found not to reach ephedrine is the Royal Decree of 6 September 2017 at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel, with the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · Updated September 20, 2026

Ephedrine in Belgium, full detail →

Etizolam

Legal status: Etizolam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name etizolam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is a thienodiazepine rather than a true benzodiazepine, and Belgium lists it by name in the same annex as the benzodiazepines rather than relying on any class description.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to etizolam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the thienodiazepine is named in the third annex in its own right. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to etizolam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no Belgian authorised medicine containing etizolam, so a lawfully obtained supply is the part that would have to be established. No route specific to etizolam was found in this dossier and none has been invented for it.
Documentation: Carry documents that show where the supply lawfully came from. The limb is not excluded, but a substance with no Belgian authorised product gives you nothing ordinary to present. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name etizolam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Etizolam in Belgium, full detail →

Fentanyl

Legal status: Fentanyl is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name fentanyl and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The analogues that share its name in the street literature are not reached by this entry; the Belgian list is closed and each analogue would need its own printed entry or a printed generic family.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to fentanyl is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I and the street analogues that share its name are not inside that entry. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to fentanyl is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Fentanyl is dispensed as patches and other authorised forms, so a patient may well be carrying one. No route specific to fentanyl was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber letter naming the patient, the strength, the dosing interval and the treatment period, and keep the supply inside three months. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name fentanyl and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Fentanyl in Belgium, full detail →

Gabapentin

Legal status: Gabapentin is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is gabapentine with a stated start date of 19 July 2026. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The start date is part of the entry. This is a new control with a stated commencement, and conduct before that date is not reached by it.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to gabapentin is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the control commenced on a stated date rather than on the publication of the amending decree. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to gabapentin is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Gabapentin is an ordinary prescribed medicine, and the control is new enough that a patient may hold a supply dispensed before it commenced. No route specific to gabapentin was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging, and note that this entry applies from 19 July 2026, so older guidance describing gabapentin as uncontrolled in Belgium is out of date rather than wrong at the time it was written. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Gabapentin in Belgium, full detail →

GBL

Legal status: GBL is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex V, where the entry is GBL with gamma-butyrolactone given in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex V is a distinct list with its own articles 49 to 61, so this substance is reached through a different part of the decree from the Annex I to IV substances.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to GBL is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the routing runs through the Annex V articles rather than through the Annex I to IV machinery. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex V is reached through its own articles 49 to 61 rather than through the Annex I to IV machinery, so what differs here is the routing into article 2bis and not the ladder it leads to.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to GBL is Annex V, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no authorised Belgian medicine containing it, and its ordinary uses are industrial rather than clinical. No route specific to GBL was found in this dossier and none has been invented for it.
Documentation: Carry documentation for a legitimate industrial or laboratory use if that is the context, because the substance has ordinary non medical uses and Annex V exists precisely to regulate that kind of trade. The placement at Annex V was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex V, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is GBL with gamma-butyrolactone given in brackets · read at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

GBL in Belgium, full detail →

GHB

Legal status: GHB is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the abbreviation GHB and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its precursor lactone is listed separately in Annex V, so the two closely related materials are governed by different parts of the same decree.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to GHB is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the substance is named in the second limb of Annex II while its precursor sits in Annex V. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to GHB is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Authorised medicine forms of this substance exist in some countries for narcolepsy. No route specific to GHB was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging if a narcolepsy medicine containing this substance was prescribed to you, with a prescriber letter stating the indication and the treatment period. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the abbreviation GHB and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

GHB in Belgium, full detail →

Heroin

Legal status: Heroin is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name heroin and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its metabolite morphine is a separate printed entry in the same limb, so both the prodrug and the active compound are listed in their own right.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to heroin is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I alongside the classic narcotics. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to heroin is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. A lawfully obtained heroin medicine for a traveller is not something this dossier records. No route specific to heroin was found in this dossier and none has been invented for it.
Documentation: Carry no expectation that a document route is practically available. Supervised treatment programmes where they exist are not a traveller exception and this row does not describe one. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name heroin and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Heroin in Belgium, full detail →

HHC

Legal status: HHC is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is one naming HHC together with the related entries printed alongside it in the current national list. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Belgium reached this one through its own national annex rather than through an international schedule, which is what the dossier means by a national list entry.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to HHC is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the semi synthetic cannabinoid is named in the national annex rather than caught by the group 4 family. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to HHC is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. The dossier records no authorised Belgian medicine containing this cannabinoid, and a shop purchase abroad is not a lawfully obtained medicine. No route specific to HHC was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on a shop receipt. Products sold openly in other countries under this name are named entries in the Belgian annex, and a retail purchase abroad is not a lawfully obtained medicine. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is one naming HHC together with the related entries printed alongside it in the current national list · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

HHC in Belgium, full detail →

Hydrocodone

Legal status: Hydrocodone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name hydrocodone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is listed in the first limb of Annex I rather than the second limb where codeine sits, so two closely related opioids are in different limbs of the same annex.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to hydrocodone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I, a stricter limb than the one carrying codeine. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to hydrocodone is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Hydrocodone is dispensed as a medicine in a number of countries. No route specific to hydrocodone was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging with a prescriber letter naming the patient, the dose and the treatment period, and keep the quantity inside three months of treatment. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name hydrocodone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Hydrocodone in Belgium, full detail →

Ketamine

Legal status: Ketamine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is the name ketamine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its fluorinated analogue is listed separately in Annex II limb B, so the parent anaesthetic sits in a less strict annex than the analogue.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to ketamine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the anaesthetic is named in the fourth annex rather than in Annex II, where its analogue sits. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to ketamine is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Ketamine is an authorised anaesthetic and analgesic. No route specific to ketamine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging where ketamine was prescribed to you, with a prescriber letter naming the indication, the dose and the treatment period. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Ketamine in Belgium, full detail →

Khat

Legal status: Khat is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb C, where the entry is khat, also printed as qat, covering all parts of Catha edulis that contain cathinone. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The entry is keyed to content rather than to the plant alone, and the cathinone it names has its own separate entry in Annex II limb A.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to khat is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the plant material is controlled through the alkaloid content the entry specifies. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb C is the plant material limb, keyed to what the material contains, and it too settles the traveller document question rather than the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to khat is Annex IV limb C, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Plant material is not a medicine and no lawfully obtained dispensed form of it is recorded. No route specific to khat was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that fresh leaf is treated differently from dried leaf. The entry reaches all parts of the plant that carry the named alkaloid. The placement at Annex IV limb C was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb C, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is khat, also printed as qat, covering all parts of Catha edulis that contain cathinone · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Khat in Belgium, full detail →

Kratom

Legal status: Kratom is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb C, where the entry is kratom, covering all parts of Mitragyna speciosa that contain mitragynine. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The entry is keyed to mitragynine content, which is why the 7-hydroxy metabolite row in this table comes out differently: material can be controlled by what it contains even where an isolated compound is not named.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to kratom is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the plant material is reached through the named alkaloid its entry specifies. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb C is the plant material limb, keyed to what the material contains, and it too settles the traveller document question rather than the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to kratom is Annex IV limb C, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. There is no dispensed medicine form of this plant material recorded for Belgium. No route specific to kratom was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on the fact that this material is sold openly in other countries. The Belgian entry reaches all parts of the plant that contain the named alkaloid. The placement at Annex IV limb C was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb C, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is kratom, covering all parts of Mitragyna speciosa that contain mitragynine · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Kratom in Belgium, full detail →

Lorazepam

Legal status: Lorazepam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name lorazepam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is another individually named Annex III benzodiazepine, and it is one of the members that the benzodiazepines row in this table resolves to.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to lorazepam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the benzodiazepine is named in the third annex. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to lorazepam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Lorazepam is in routine clinical use. No route specific to lorazepam was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging with a prescriber letter stating the patient, the dose and the period of treatment, and keep the supply to three months or less. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name lorazepam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Lorazepam in Belgium, full detail →

LSA (Morning Glory)

Legal status: LSA (ergine) is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: Annex II names lysergide and Annex IV limb B names selected lysergamides including 1P-LSD, LSZ and methylisopropyllysergamide, but neither names ergine or lysergic acid amide, and Annex IVA carries no generic ergoline or lysergamide family. The dossier puts this one squarely: LSA is not LSD. Belgium names particular lysergamides and has no generic ergoline structure, so similarity to lysergide is not enough to bring this compound in. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and LSA (ergine) is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the absence was recorded only after the named lysergamide entries and the eight generic families were both checked. Where a material described by this name in fact contains a listed substance, article 2(14) reaches it as a preparation and the article 2bis ladder then applies to that content.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. LSA (ergine) is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no placement, because the named lysergamide entries do not include this one. No route specific to LSA (ergine) was found in this dossier and none has been invented for it.
Documentation: Carry the distinction with you rather than the family resemblance. Several lysergamides are named entries in Belgium and this one is not, so the answer turns on which compound is actually present. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for LSA (ergine) with the result that there is no entry: Annex II names lysergide and Annex IV limb B names selected lysergamides including 1P-LSD, LSZ and methylisopropyllysergamide, but neither names ergine or lysergic acid amide, and Annex IVA carries no generic ergoline or lysergamide family · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

LSA (Morning Glory) in Belgium, full detail →

LSD

Legal status: LSD is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is lysergide, with the dextrorotatory form marked and the familiar abbreviations given in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The entry names lysergide specifically. Other lysergamides are reached only where they are separately printed in Annex IV limb B, which is why the ergine row in this table comes out the other way.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to LSD is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the compound is named in the first limb of Annex II under its International Nonproprietary Name. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to LSD is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This entry sits in the excluded limb, so the exception does not open for it. No route specific to LSD was found in this dossier and none has been invented for it.
Documentation: Carry no expectation of any document route. The limb is excluded and no authorised Belgian medicine containing lysergide is recorded. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is lysergide, with the dextrorotatory form marked and the familiar abbreviations given in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

LSD in Belgium, full detail →

MDA

Legal status: MDA is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is tenamfetamine with MDA given in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The annex prints the International Nonproprietary Name first, so a search run on the street abbreviation alone could miss the entry altogether.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to MDA is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the compound is named in the first limb of Annex II under an International Nonproprietary Name that is not the abbreviation the street uses. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to MDA is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. The excluded limb applies whichever of the two printed designations is used. No route specific to MDA was found in this dossier and none has been invented for it.
Documentation: Carry the point about the printed name. The annex uses tenamfetamine for this compound, and a document search on three letters would not find it. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is tenamfetamine with MDA given in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

MDA in Belgium, full detail →

MDMA

Legal status: MDMA is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is the abbreviation MDMA and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Belgium prints the abbreviation itself for this one, while the closely related compound in the row above is printed under an International Nonproprietary Name instead.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to MDMA is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the compound is named in the first limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to MDMA is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This is an excluded limb placement, and the dossier records no authorised Belgian medicine containing the substance. No route specific to MDMA was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on clinical trial programmes elsewhere. The limb is the excluded one and no Belgian authorised product is recorded, so there is no lawfully obtained medicine to document. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the abbreviation MDMA and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

MDMA in Belgium, full detail →

MDPV

Legal status: MDPV is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the abbreviation MDPV and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is a cathinone derivative listed by name in the second limb of Annex II rather than left to a generic family, and the annexes contain no general cathinone derivatives group.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to MDPV is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the synthetic cathinone is named in the second limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to MDPV is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing this cathinone derivative is recorded. No route specific to MDPV was found in this dossier and none has been invented for it.
Documentation: Carry documents describing the actual material rather than the abbreviation. Cathinone derivatives are listed one by one in Belgium, so identity is what decides the result. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the abbreviation MDPV and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

MDPV in Belgium, full detail →

Memantine

Legal status: Memantine is not a named controlled drug in Belgium, and the position that applies to it is a medicines or product one. The check found no controlled drug entry; the position is a medicines one, with the official Belgian medicine database listing authorised memantine products including Ebixa and recording a specialist first prescription route with general practitioner follow up. The prescribing arrangement recorded here is a medicines rule about who may start the treatment, and it is not a schedule placement. The controlled drug lists in the Royal Decree of 6 September 2017 do not reach it, and under the delegated model a substance outside the list the King has settled is not governed by article 2bis of the Law of 24 February 1921 at all. That is a statement about the drug decree only, and it does not make the substance unregulated.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and memantine is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. Here the medicines regime supplies the rule and the drug decree does not. Supplying a prescription only medicine outside the medicines rules remains an offence under those rules, which this row does not set out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Memantine is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. The first prescription arrangement recorded for Belgium is about starting treatment inside Belgium and is not the traveller document exception. No route specific to memantine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging as you would for any prescribed medicine, and be aware that Belgium records a specialist first prescription route with general practitioner follow up for this one. The medicines position was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for memantine with the result that there is no controlled drug entry · the position is a medicines one, with the official Belgian medicine database listing authorised memantine products including Ebixa and recording a specialist first prescription route with general practitioner follow up · read at https://basededonneesdesmedicaments.be/medicament/62bc2cb68ab5583c18a52667-62bc07a9ac75b92c42ca0bb8 on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Memantine in Belgium, full detail →

Mephedrone (4-MMC)

Legal status: Mephedrone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name mephedrone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its ring isomer is listed separately in the same limb, which shows that Belgium reaches these cathinones by naming each one rather than by a structural family.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to mephedrone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the cathinone is named in the second limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to mephedrone is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing this cathinone is recorded. No route specific to mephedrone was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that a positional isomer of this compound shares its entry. Belgium prints these cathinones individually and the isomers are separate entries. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name mephedrone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Mephedrone (4-MMC) in Belgium, full detail →

Mescaline

Legal status: Mescaline is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is the name mescaline and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The cacti that contain it are handled separately in Annex IV limb C, keyed to the presence of this same alkaloid, so the compound and the plant have different placements.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to mescaline is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the alkaloid is named in the first limb of Annex II and the plant material is listed elsewhere. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to mescaline is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. The alkaloid sits in the excluded limb, while the cacti that contain it are answered by a separate row. No route specific to mescaline was found in this dossier and none has been invented for it.
Documentation: Carry no expectation of a document route for the alkaloid, and read this row together with the separate entry that reaches the cacti containing it. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name mescaline and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Mescaline in Belgium, full detail →

Methadone

Legal status: Methadone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name methadone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is named in the first limb of Annex I even though its ordinary use in Belgium is as a substitution treatment, so the annex placement and the clinical role are different things.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to methadone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I although its ordinary Belgian use is substitution treatment. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to methadone is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Methadone is dispensed under substitution treatment programmes. No route specific to methadone was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber or programme letter stating the daily dose and the period covered, and expect the three month personal use limit to be applied strictly to a liquid supply. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name methadone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Methadone in Belgium, full detail →

Methamphetamine

Legal status: Methamphetamine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name methamphetamine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It sits in the second limb of Annex II alongside its parent stimulant rather than in the first limb, and the limb is a finding in its own right.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to methamphetamine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the stimulant is named in the second limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to methamphetamine is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing this stimulant is recorded. No route specific to methamphetamine was found in this dossier and none has been invented for it.
Documentation: Carry documents for the actual material. The Belgian entry is a named one, and the placement does not turn on purity, form or the street description of the product. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name methamphetamine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Methamphetamine in Belgium, full detail →

Methaqualone (Quaaludes)

Legal status: Methaqualone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name methaqualone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It remains a named entry in Belgium notwithstanding that it was withdrawn as a medicine decades ago, so a historical withdrawal did not remove the schedule placement.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to methaqualone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the sedative is named in the second limb of Annex II despite having no current medicine role. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to methaqualone is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing it is recorded, so there would be nothing lawfully obtained to carry. No route specific to methaqualone was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that a medicine withdrawn long ago has fallen off the list. It is still printed in the annex. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name methaqualone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Methaqualone (Quaaludes) in Belgium, full detail →

Methylone

Legal status: Methylone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is methylone with the alternative designation bk-MDMA in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The annex prints the ketone designation alongside the common name, which means a search on either form finds the entry.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to methylone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the cathinone is named in the second limb of Annex II under two designations. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to methylone is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing it is recorded under either designation. No route specific to methylone was found in this dossier and none has been invented for it.
Documentation: Carry the point that the entry carries two designations. The material is a named Belgian entry under either of them. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is methylone with the alternative designation bk-MDMA in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Methylone in Belgium, full detail →

Methylphenidate

Legal status: Methylphenidate is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is the name methylphenidate and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is a very widely prescribed medicine that nonetheless sits in the second limb of Annex II, which is exactly the situation the traveller document rule was written to handle.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to methylphenidate is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the stimulant is named in the second limb of Annex II while remaining an ordinary prescribed medicine. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to methylphenidate is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. A patient carrying a lawfully obtained supply is within the situation the exception addresses. No route specific to methylphenidate was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging with a prescriber letter naming the patient, the daily dose and the treatment period, and keep the supply to no more than three months of treatment. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name methylphenidate and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Methylphenidate in Belgium, full detail →

Mitragynine

Legal status: Mitragynine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is the name mitragynine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The plant that produces it is separately controlled in Annex IV limb C through its content of this same alkaloid, while the 7-hydroxy metabolite is not named at all, so three related questions get three different answers.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to mitragynine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the alkaloid is named in the fourth annex and the plant material is listed separately. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to mitragynine is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing the alkaloid is recorded. No route specific to mitragynine was found in this dossier and none has been invented for it.
Documentation: Carry the three way distinction with you. The named alkaloid, the plant material that contains it and the unnamed metabolite are answered by three different rows in this table. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Mitragynine in Belgium, full detail →

Modafinil

Legal status: Modafinil is not a named controlled drug in Belgium, and the position that applies to it is a medicines or product one. The check found no controlled drug entry; the AFMPS records that Provigil is the only modafinil medicine authorised and marketed in Belgium and that its accepted indication is narcolepsy. A single authorised product with a single accepted indication is a medicines position, and it is not an annex placement. The controlled drug lists in the Royal Decree of 6 September 2017 do not reach it, and under the delegated model a substance outside the list the King has settled is not governed by article 2bis of the Law of 24 February 1921 at all. That is a statement about the drug decree only, and it does not make the substance unregulated.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and modafinil is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. Here the medicines regime rather than the drug decree is what governs this one. Supplying a prescription only medicine outside the medicines rules remains an offence under those rules, which this row does not set out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Modafinil is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. The narrow indication recorded is about prescribing inside Belgium and does not change the traveller document rule. No route specific to modafinil was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging, and be aware that Belgium records only one authorised modafinil medicine and one accepted indication for it, so a supply prescribed abroad for a different indication may attract questions. The medicines position was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for modafinil with the result that there is no controlled drug entry · the AFMPS records that Provigil is the only modafinil medicine authorised and marketed in Belgium and that its accepted indication is narcolepsy · read at https://www.afmps.be/fr/news/news_modafinil on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Modafinil in Belgium, full detail →

Morphine

Legal status: Morphine is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name morphine and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Opium, from which it is obtained, is a separate printed entry in the same limb, and heroin, which metabolises to it, is another, so the same limb carries all three.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to morphine is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I alongside the opium it is obtained from. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to morphine is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Morphine is dispensed for pain in ordinary clinical practice. No route specific to morphine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber letter naming the patient, the strength, the dosing and the treatment period, and keep the supply inside three months of treatment. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name morphine and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Morphine in Belgium, full detail →

MXE

Legal status: MXE (methoxetamine) is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is methoxetamine with MXE given in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Its parent anaesthetic ketamine is in Annex IV limb B, so this analogue is in a stricter annex than the compound it derives from.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to MXE (methoxetamine) is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the dissociative analogue is named in the second limb of Annex II while its parent sits in Annex IV. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to MXE (methoxetamine) is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing this dissociative analogue is recorded. No route specific to MXE (methoxetamine) was found in this dossier and none has been invented for it.
Documentation: Carry the annex difference in mind. This analogue and its parent are in different annexes, so a rule read for one does not carry across to the other. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is methoxetamine with MXE given in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

MXE in Belgium, full detail →

Nicotine

Legal status: Nicotine is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: a search of Annexes I to V and all eight Annex IVA families for nicotine returned nothing, and the separate Belgian rules on tobacco products, electronic cigarettes and nicotine medicines produce no narcotic or psychotropic classification. Three separate second route regimes were examined here, tobacco products, electronic cigarettes and nicotine medicines, and none of them turns the substance into a controlled drug. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and nicotine is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the drug decree is not the instrument that governs nicotine in any of its product forms. The consequences that do attach in Belgium come from the product regimes named in this row, and this table does not set them out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Nicotine is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no annex placement, and the tobacco, electronic cigarette and nicotine medicine rules that do apply are product rules rather than carriage documents. No route specific to nicotine was found in this dossier and none has been invented for it.
Documentation: Carry no inference about vaping rules, age limits or product notification from this row. It records the absence from the drug annexes only, and the other regimes were not audited. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for nicotine with the result that there is no entry: a search of Annexes I to V and all eight Annex IVA families for nicotine returned nothing, and the separate Belgian rules on tobacco products, electronic cigarettes and nicotine medicines produce no narcotic or psychotropic classification · read at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Nicotine in Belgium, full detail →

Nimetazepam

Legal status: Nimetazepam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name nimetazepam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is one of the less familiar Annex III benzodiazepines and it is printed by name, which is another instance of Belgium refusing a class wide description.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to nimetazepam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the benzodiazepine is named in the third annex in its own right. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to nimetazepam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing it is recorded, so a lawful source would have to be shown. No route specific to nimetazepam was found in this dossier and none has been invented for it.
Documentation: Carry documents showing a lawful origin if you hold any of this substance. The limb is not excluded, but no Belgian authorised product is recorded for it. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name nimetazepam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Nimetazepam in Belgium, full detail →

Nitrous Oxide

Legal status: Nitrous oxide is controlled in Belgium by a product specific prohibition rather than by a schedule entry. The Royal Decree of 11 March 2024, article 1(1), prohibits importing, exporting, transit, manufacture, storage, labelling, transport, possession, brokerage, sale, offering, prescription, supply and acquisition of nitrous oxide, whether physically or online. Article 1(2) excepts medical, technical and food additive purposes, so the lawful uses are defined by purpose rather than by quantity. This is a separate instrument from the 2017 annexes, and the substance is not placed in Annexes I to V at all; the prohibition does the work that a schedule entry does elsewhere.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach comes from a different instrument. Breaches other than personal use are routed by article 3 of the Royal Decree of 11 March 2024 to article 2bis of the Law of 24 February 1921, so the ordinary band is three months to five years of imprisonment with a fine of EUR 1,000 to 100,000 under article 2bis §1, ten to fifteen years under article 2bis §3 for its stated aggravations including where use following the offence causes death, and a ceiling of fifteen to twenty years under article 2bis §4 where the offence concerns a child under twelve or participation as a leader in an association. Twenty years under article 2bis §4 is the maximum. Personal use breaches are routed instead to article 2ter, points 1 to 3, which carries a markedly lower ladder, and that personal use route does not erase the exposure for aggravated supply conduct.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Nitrous oxide is not in Annexes I to IV, so the exception has nothing to except it from, and the question runs instead through article 1(2) of the Royal Decree of 11 March 2024, which excepts medical, technical and food additive purposes. That is a purpose based exception in a different instrument and it is not a patient carriage document rule. No route specific to nitrous oxide was found in this dossier and none has been invented for it.
Documentation: Carry evidence of the excepted purpose rather than a prescription, because article 1(2) of the Royal Decree of 11 March 2024 works by medical, technical or food additive purpose and not by a dispensing document. A catering or medical supply record showing the intended use is what answers the prohibition in article 1(1). The 2024 decree was read on 18 September 2026 at the Moniteur belge publication. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 11 March 2024, articles 1 and 3, with article 1(1) carrying the prohibition, article 1(2) the medical, technical and food additive exceptions, and article 3 routing other breaches to article 2bis of the Law of 24 February 1921 while personal use breaches go to article 2ter points 1 to 3 · read at https://www.ejustice.just.fgov.be/cgi/article_body.pl?language=fr&caller=summary&pub_date=24-03-29&numac=2024002967 on 18 September 2026 · nitrous oxide is not placed in Annexes I to V of the Royal Decree of 6 September 2017 at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel, and the 1921 Law bilingual consolidation is at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · Updated September 20, 2026

Nitrous Oxide in Belgium, full detail →

Opium

Legal status: Opium is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is opium, defined in the annex as the thickened latex of the opium poppy. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The definition is part of the entry: it is keyed to the latex, and the morphine obtained from it is a separate printed entry in the same limb.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to opium is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the plant product is named and defined in the first limb of Annex I. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to opium is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No dispensed opium medicine for a traveller is recorded. No route specific to opium was found in this dossier and none has been invented for it.
Documentation: Carry no assumption that poppy derived material in any form falls under this entry. The annex defines it as the thickened latex, and other poppy products are answered by the entries that name them. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is opium, defined in the annex as the thickened latex of the opium poppy · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Opium in Belgium, full detail →

Oxycodone

Legal status: Oxycodone is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex I limb A, where the entry is the name oxycodone and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is in the first limb of Annex I with the other strong opioids, and its placement is by name rather than through any morphinan family description.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to oxycodone is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid is named in the first limb of Annex I by name rather than through any morphinan family description. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex I limb A is where Belgium prints the classic narcotics. The limb settles the traveller document question rather than this ladder: article 2bis reaches any substance the King has listed, whichever annex prints it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to oxycodone is Annex I limb A, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Oxycodone is dispensed for pain, commonly in modified release form, in ordinary clinical practice. No route specific to oxycodone was found in this dossier and none has been invented for it.
Documentation: Carry the prescription, the original dispensing packaging and a prescriber letter naming the patient, the strength, the dosing schedule and the treatment period, and hold the supply to three months or less. The placement at Annex I limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex I limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name oxycodone and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20I_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Oxycodone in Belgium, full detail →

PCP

Legal status: PCP is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb B, where the entry is phencyclidine with PCP given in brackets. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The annex prints the full chemical name with the abbreviation in brackets, so the entry is found under either form.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to PCP is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the dissociative is named in the second limb of Annex II. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb B is not excluded from the traveller document route. The limb answers that question and not this one, because the band above applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to PCP is Annex II limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian human medicine containing it is recorded. No route specific to PCP was found in this dossier and none has been invented for it.
Documentation: Carry documents for the material itself. The entry is a named one and its former veterinary history does not create a current Belgian route. The placement at Annex II limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is phencyclidine with PCP given in brackets · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

PCP in Belgium, full detail →

Peyote

Legal status: Peyote is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb C, where the entry is peyote, covering all parts of Lophophora cacti that contain mescaline. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The entry is keyed to alkaloid content and to a named genus, and the alkaloid it names has its own separate entry in Annex II limb A.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to peyote is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the cactus material is controlled through the alkaloid content the entry specifies. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb C is the plant material limb, keyed to what the material contains, and it too settles the traveller document question rather than the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to peyote is Annex IV limb C, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Plant material is not a dispensed medicine and no lawful dispensing route for it is recorded. No route specific to peyote was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on an ornamental plant argument. The entry reaches all parts of the named cacti that carry the named alkaloid. The placement at Annex IV limb C was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb C, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is peyote, covering all parts of Lophophora cacti that contain mescaline · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Peyote in Belgium, full detail →

Pink Cocaine / Tusi

Legal status: Not applicable as a single status, and not because the decree is silent. Pink cocaine, sold as tusi, is a street label rather than a substance: the Belgian lists contain no entry named pink cocaine and no entry named tusi, and the powder has no fixed composition. Article 2(14) of the Royal Decree of 6 September 2017 reaches a preparation, defined as a solution or mixture in any physical state containing one or more substances, so the actual contents decide the result. The constituents commonly reported under the name are answered separately in this table: ketamine is a named entry in Annex IV limb B and MDMA is a named entry in Annex II limb A, and those rows, not this one, carry the schedule placements. The same name can produce different results from one sample to the next, and no single terminal status can honestly be stated for the label itself.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. The exposure here is real but it is inherited. Where a powder sold under this label contains a listed substance, article 2(14) reaches it as a preparation and article 61 of the decree routes the breach to article 2bis of the Law of 24 February 1921. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. The ladder that applies is the one attaching to what the sample actually contains, so two powders sold under the same name can sit at different points on it.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. There is no placement to attach, because the label is not a substance and has no schedule entry of its own. The placement that matters is the one belonging to whatever the material actually contains, and where that is a first limb Annex II substance the exception is excluded while for other placements it is not. No route specific to a street label was found in this dossier and none has been invented for it.
Documentation: Carry nothing on the strength of this name, because it identifies no substance and no document can vouch for a powder of unknown composition. The Belgian annexes were read on 18 September 2026 and contain no entry under this label or under tusi. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, article 2(14) on preparations together with Annexes I to V and articles 8 and 61, checked for the label pink cocaine and returning no entry under that name, so the placements that matter belong to the constituent rows in this table · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version and the Moniteur belge controls · Updated September 20, 2026

Pink Cocaine / Tusi in Belgium, full detail →

Poppers

Legal status: Not applicable as a class status, and not because the decree is silent. Poppers is a product class rather than one compound: amyl, pentyl, isopropyl and isobutyl nitrites are different chemicals and cannot be given one schedule result. None of them is named in Annexes I to IV of the Royal Decree of 6 September 2017, so the controlled drug answer is negative for each, but that is not the whole question. The Belgian medicine and product law position has to be resolved for the actual alkyl nitrite and the actual product presentation, and the amyl nitrite search recorded in this table did not establish a current authorised Belgian product. The row for that nitrite, not this one, carries what was and was not established. No single terminal status can honestly be stated for the label.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. No ceiling under article 2bis of the Law of 24 February 1921 attaches to the street label at all, because nothing is identified for it to attach to: none of the alkyl nitrites sold under this name is in Annexes I to IV. Any consequence would come from the medicines or product regimes applying to the specific nitrite and the specific presentation, and this row identifies no such consequence because the underlying product position was not established. That is a statement about which instrument would have to supply a penalty, not a statement that none could.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. There is no placement to attach here, because none of the alkyl nitrites sold under this name is in Annexes I to IV. The relevant question is a medicines and product one for the particular nitrite in the particular presentation, and this table records that no current Belgian authorised product was established for the best documented member of the class. No route specific to the product class was found in this dossier and none has been invented for it.
Documentation: Carry the actual product and its labelling rather than the word, because the word covers several different chemicals with different answers. The Belgian annexes were read on 18 September 2026 and name none of them. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls.

Belgium, Royal Decree of 6 September 2017, article 2(14) on preparations together with Annexes I to V and articles 8 and 61, checked for the label poppers and returning no entry under that name, so the placements that matter belong to the constituent rows in this table · read at https://basededonneesdesmedicaments.be on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version and the Moniteur belge controls · Updated September 20, 2026

Poppers in Belgium, full detail →

Pregabalin

Legal status: Pregabalin is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is pregabaline with a stated start date of 19 July 2026, and, for preparations composed with one or more other substances that stay at or below 330 mg per dosage unit or 5 percent in undivided form, also at Annex IV limb C with the same start date. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Like the related anticonvulsant in this table, the entry carries its own commencement date, and the date is part of what the entry says.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to pregabalin is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the control commenced on a stated date printed in the annex itself. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller carrying the medicine in international traffic is article 3, paragraph 4, point 4 of the Royal Decree of 6 September 2017, which provides that the decree does not apply to that carriage. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine carried by a traveller in international traffic, in a quantity that does not exceed three months of treatment, for that traveller's own personal use, and lawfully obtained, and it expressly excludes the substances listed in Annex II limb A. Pregabalin is printed at Annex IV limb B and, for preparations composed with one or more other substances that stay at or below 330 mg per dosage unit or 5 percent in undivided form, also at Annex IV limb C, both with effect from 19 July 2026. Article 3, paragraph 4, point 4 excludes only Annex II limb A, so neither limb removes the exception, and the exception can apply on its own terms where the medicine was lawfully obtained and the international travel, personal use, three month and certificate conditions are all met. To rely on it, the traveller must be able to present a certificate from their own authority or from a health professional, to the competent officials referred to in article 7 of the Law of 24 February 1921. Pregabalin's control commenced on the printed date of 19 July 2026, and the article 3 exception stated above is the only traveller route this entry states.
Documentation: Carry a certificate from your own authority or from a health professional, to present to the competent officials referred to in article 7 of the Law of 24 February 1921. Article 3, paragraph 4, point 4 of the Royal Decree of 6 September 2017 is the only document exception this entry states. The exception covers the carriage by travellers in international traffic of medicines, for their personal use, lawfully obtained, in a quantity not exceeding three months of treatment. Note the commencement date of 19 July 2026 printed on this entry. The placement at Annex IV limb B was read on 18 September 2026 in the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The same consolidated version prints a pregabaline entry in Annex IV limb C, for preparations, with the same start date. That annex consolidation is valid from 29 March 2026, following the amending Royal Decree published 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is pregabaline with a stated start date of 19 July 2026 · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the printed limb C entry for preparations is pregabaline with a stated start date of 19 July 2026 and the 330 mg per dosage unit or 5 percent condition · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · article 3, paragraph 4, point 4 of the same decree and article 7 of the Law of 24 February 1921 for the traveller's document exception, Dutch Justel consolidation read at https://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?cn=2017090603&la=N&language=nl&table_name=wet on 7 October 2026 · Updated October 8, 2026

Pregabalin in Belgium, full detail →

Psilocybin

Legal status: Psilocybin is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex II limb A, where the entry is the name psilocybine, printed in its continental spelling, and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The annex prints the continental spelling, which is worth knowing because a document search run on the English spelling alone can return nothing and be misread as absence.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to psilocybin is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the compound is named in the first limb of Annex II under its continental spelling. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex II limb A is the one limb excluded from the traveller document route, so the limb changes what a patient may lawfully carry rather than what this ladder reaches.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to psilocybin is Annex II limb A, which is the one limb the rule excludes, so the document exception does not open for it and a foreign prescription does not create one. This is an excluded limb placement, so the document exception does not open for it. No route specific to psilocybin was found in this dossier and none has been invented for it.
Documentation: Carry no expectation of a document route, and note that the annex prints the name in its continental spelling. A search that returned nothing may have used the wrong spelling rather than found an absence. The placement at Annex II limb A was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex II limb A, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name psilocybine, printed in its continental spelling, and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Psilocybin in Belgium, full detail →

Quetiapine

Legal status: Quetiapine is not a named controlled drug in Belgium, and the position that applies to it is a medicines or product one. The check found no controlled drug entry; the official Belgian medicine database lists authorised quetiapine products, which is a medicines position rather than a schedule placement. An authorised medicine is regulated by the medicines regime, and this row records that regime rather than a controlled drug status. The controlled drug lists in the Royal Decree of 6 September 2017 do not reach it, and under the delegated model a substance outside the list the King has settled is not governed by article 2bis of the Law of 24 February 1921 at all. That is a statement about the drug decree only, and it does not make the substance unregulated.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and quetiapine is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. Here the medicines regime supplies the rule for this antipsychotic. Supplying a prescription only medicine outside the medicines rules remains an offence under those rules, which this row does not set out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Quetiapine is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. Authorised Belgian products exist for this substance, so an ordinary prescribed supply is a medicines question rather than a controlled drug one. No route specific to quetiapine was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging as for any prescribed medicine. Belgium lists authorised quetiapine products, so an equivalent is available in the country. The medicines position was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for quetiapine with the result that there is no controlled drug entry · the official Belgian medicine database lists authorised quetiapine products, which is a medicines position rather than a schedule placement · read at https://basededonneesdesmedicaments.be/usage-humain/medicaments/630f499730c18662e6499515 on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Quetiapine in Belgium, full detail →

Salvia divinorum

Legal status: Salvia divinorum is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb C, where the entry is Salvia divinorum plant material containing salvinorin A. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The entry names the plant material and keys it to the active constituent, and the constituent itself is not given a separate named entry.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to Salvia divinorum is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the plant material is controlled through the constituent named in its entry. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb C is the plant material limb, keyed to what the material contains, and it too settles the traveller document question rather than the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to Salvia divinorum is Annex IV limb C, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No dispensed form of this plant is recorded for Belgium, and its active constituent has no separate entry that could carry one. No route specific to Salvia divinorum was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on the fact that this plant is sold legally in some countries. The Belgian annex names the material and keys it to its active constituent. The placement at Annex IV limb C was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb C, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is Salvia divinorum plant material containing salvinorin A · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Salvia divinorum in Belgium, full detail →

Synthetic Cannabinoids (K2 / Spice)

Legal status: Synthetic cannabinoids is controlled in Belgium, but not by being named. It is reached by the generic definitions in Annex IVA group 4, which print the controlled core structures and their substituent definitions, and the operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. Annex IVA is the one part of the list that is open, and it is open only inside the eight precisely printed generic chemical families; a structure that does not fit the printed core and substituent ranges is outside it. This slug is not a street label in Belgium: it corresponds to a printed generic family in the annex, with defined core structures and substituent ranges, so it has a real terminal status. The family prints indole, indazole, benzodiazole and pyrrole cores, and a cannabinoid built on a different core is outside it. That is why cannabinol, which has a dibenzopyran core, comes out the other way in this table.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to synthetic cannabinoids is the article 2bis ladder in the Law of 24 February 1921, reached through the same routing article as a named substance, and here the control is a printed structural family rather than a list of product names. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IVA is the generic family limb, and a family result carries the same article 2bis exposure as a named entry: what differs is how the substance is proved to be listed, not what follows once it is.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Synthetic cannabinoids is reached through the generic family in Annex IVA group 4 rather than through a named entry, and that family is not the excluded limb, so the placement does not shut the exception out; whether a lawfully obtained medicine exists to carry is a separate question this row does not answer. No product sold under this class name is an authorised Belgian medicine on anything this dossier records. No route specific to synthetic cannabinoids was found in this dossier and none has been invented for it.
Documentation: Carry the structural definition in mind rather than a product name. Group 4 prints the cores it reaches, so a new compound is inside or outside the family on its structure and not on its marketing. The generic family at Annex IVA group 4 was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IVA group 4, the synthetic cannabinoid derivatives family, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the basis relied on is the generic definitions in Annex IVA group 4, which print the controlled core structures and their substituent definitions · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Synthetic Cannabinoids (K2 / Spice) in Belgium, full detail →

THC-P

Legal status: THC-P is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is THCP with tetrahydrocannabiphorol given in brackets, together with its isomers, and a separately printed acid form. The entry is what proves listing. The operative provisions come from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The dossier is explicit that this is a direct named entry and not an inference from the tetrahydrocannabinol entry with its printed pentyl side chain, which reaches a different set of isomers.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to THC-P is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the compound and its acid form are named entries in the fourth annex in their own right. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to THC-P is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. No authorised Belgian medicine containing this cannabinoid or its acid form is recorded. No route specific to THC-P was found in this dossier and none has been invented for it.
Documentation: Carry no reliance on a hemp derived label. This compound has its own named entry and its acid form is printed separately, so neither is reached only through the tetrahydrocannabinol entry. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex IV limb B, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is THCP with tetrahydrocannabiphorol given in brackets, together with its isomers, and a separately printed acid form · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

THC-P in Belgium, full detail →

Tobacco

Legal status: Tobacco is not reached by the Belgian controlled drug lists on the text checked here. The search found no entry: a search of Annexes I to V and all eight Annex IVA families for tobacco and Nicotiana tabacum returned nothing, and the separate Belgian tobacco product rules produce no narcotic or psychotropic classification. The search was run on the plant name as well as the common word, which is the discipline the dossier applies throughout: the botanical name and the common name are both tried before an absence is recorded. That makes this a positive absence rather than a silence: the dossier records that before any absence was entered, the search moved through Annexes I to IV, all eight Annex IVA generic families, Annex V, product specific royal decrees, the EU precursor schedules, the AFMPS human and veterinary medicine database and the applicable food, plant, tobacco, alcohol or chemical product route. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. On this row no controlled drug ladder attaches either. Article 2bis of the Law of 24 February 1921 reaches substances the King has listed, and tobacco is not on that list, so it supplies no band, no aggravated ceiling and no fine on this row. Separate product, food, tobacco, alcohol, medicines or veterinary penalties sit outside this row unless it states one, and it states none. The reason is the classification itself rather than a lenient penalty: the plant is outside the subject matter of the drug decree entirely. The consequences that do attach in Belgium come from the product regimes named in this row, and this table does not set them out.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. Tobacco is not in Annexes I to IV at all on this row's finding, so there is nothing here for the exception to except, and a travel question about it is a medicines or product question rather than a controlled drug one. There is no annex placement, and the rules that do apply to this plant are excise and product ones. No route specific to tobacco was found in this dossier and none has been invented for it.
Documentation: Carry no inference about excise, age limits or plain packaging from this row. It records the absence from the drug annexes only, and the dossier states the other regimes were not audited. This was read on 18 September 2026 against the annex consolidation and the decree. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annexes I to V, the eight Annex IVA generic families and articles 2, 8 and 61, checked for tobacco with the result that there is no entry: a search of Annexes I to V and all eight Annex IVA families for tobacco and Nicotiana tabacum returned nothing, and the separate Belgian tobacco product rules produce no narcotic or psychotropic classification · read at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the Law of 24 February 1921 bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Tobacco in Belgium, full detail →

Tramadol

Legal status: Tramadol is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex IV limb B, where the entry is the name tramadol and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It sits in the fourth annex rather than with the Annex I opioids, so its placement is less strict than a pharmacological guess would suggest.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to tramadol is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the opioid analgesic is named in the fourth annex rather than in Annex I. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex IV limb B is the national limb, where Belgium adds entries of its own rather than importing an international schedule, and the limb bears on the traveller document rule rather than on the band.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to tramadol is Annex IV limb B, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Tramadol is dispensed for pain in ordinary clinical practice. No route specific to tramadol was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging with a prescriber letter naming the patient, the dose and the treatment period, and hold the supply to no more than three months of treatment. The placement at Annex IV limb B was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Tramadol in Belgium, full detail →

Xanax (Alprazolam)

Legal status: Alprazolam is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name alprazolam and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. It is one of the individually named benzodiazepines in Annex III: Belgium has no class wide benzodiazepine entry and resolves each member by its own printed name.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to alprazolam is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here this triazolobenzodiazepine is listed by name in the third annex. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to alprazolam is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Alprazolam is a substance with authorised medicine forms in many countries, so this is the case the rule was written for. No route specific to alprazolam was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging, with a prescriber letter naming the patient, the active substance, the dose and the treatment period, and keep the quantity inside the three month personal use limit. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name alprazolam and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Xanax (Alprazolam) in Belgium, full detail →

Zolpidem

Legal status: Zolpidem is a controlled substance in Belgium because it is listed. The Royal Decree of 6 September 2017 prints it at Annex III, where the entry is the name zolpidem and no further text. That entry proves listing and does nothing more. It carries no article number and no operative provision of its own, and every operative provision comes from the instrument named for this row, the Royal Decree of 6 September 2017, where article 2 defines the controlled substances through Annexes I to V and article 61 routes a breach back to the Law of 24 February 1921. Belgium works a delegated model: article 2bis §1 of the Law of 24 February 1921 punishes breaches concerning substances whose list is settled by the King, and the Royal Decree of 6 September 2017 supplies that list. The named lists are closed, so pharmacological resemblance, a similar spelling or a substring match cannot enlarge them. The dossier notes it separately as a non benzodiazepine hypnotic that nonetheless has its own printed Annex III entry, so it is not reached through any benzodiazepine description.
Consequences if caught: Capital exposure: none. Belgium's drug law carries no death penalty and no life sentence. What does attach to zolpidem is the article 2bis ladder in the Law of 24 February 1921, which article 61 of the decree routes a breach to once the substance is listed, and here the non benzodiazepine hypnotic is named in the third annex in its own right. Article 2bis §1 sets the ordinary band at three months to five years of imprisonment with a fine of EUR 1,000 to 100,000. Article 2bis §3 raises that to ten to fifteen years for its stated aggravations, including where use following the offence causes death. Article 2bis §4 carries the ceiling, fifteen to twenty years, where the offence concerns a child under twelve or participation as a leader in an association, so twenty years is the maximum imprisonment this statute exposes. Article 2bis §5 allows a further fine of EUR 1,000 to 100,000 in the §2 to §4 cases, which makes that fine available rather than automatic. Annex III carries most of the prescribed sedatives and hypnotics, and the limb settles the traveller document question rather than the band, which article 2bis applies to any listed substance.
If prescribed / medical: The rule that applies to a traveller here is Belgium's own and it is one rule for the whole country: article 3(4)(4) of the Royal Decree of 6 September 2017. It is a document exception rather than a schedule, and it is not a prescribing right. It covers a medicine that was lawfully obtained, carried for the traveller's own personal use, and limited to no more than three months of treatment, and it expressly excludes the substances in Annex II limb A. The placement that attaches to zolpidem is Annex III, which article 3(4)(4) does not exclude, so the exception can apply on its own terms where the medicine was lawfully obtained and the personal use and three month limits are both met. Zolpidem is an ordinary prescribed hypnotic. No route specific to zolpidem was found in this dossier and none has been invented for it.
Documentation: Carry the prescription and the original dispensing packaging with a prescriber letter stating the indication, the dose and the treatment period, and keep the supply to three months or less. The placement at Annex III was read on 18 September 2026. The annex text read is the non official consolidated version published by the AFMPS; it is informative and the Moniteur belge controls. The annex consolidation relied on here is valid from 29 March 2026, following the amending Royal Decree published on 19 March 2026, and carries a correction dated 16 July 2026.

Belgium, Royal Decree of 6 September 2017, Annex III, with articles 2, 8 and 61 of that decree and article 2bis of the Law of 24 February 1921 carrying the offence and the penalties · the printed entry relied on is the name zolpidem and no further text · read at https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20III_non%20official%20consolidated%20version.pdf on 18 September 2026 · the decree is at https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel and the 1921 Law bilingual consolidation at https://afmps.be/sites/default/files/downloads/LOI-WET-1921-02-24.pdf · the annex text is the AFMPS non official consolidated version, valid from 29 March 2026 with a correction dated 16 July 2026, and the Moniteur belge controls · Updated September 20, 2026

Zolpidem in Belgium, full detail →

Not individually verified

5 substances are not individually verified for Belgium

For these the governing national drug law is cited, but we have not verified that the substance specifically is scheduled under it. Treat them as unanswered, not as legal. Confirm with Belgium’s drug authority or your embassy.

Substance	What we found
Amanita muscaria	Not confirmed. The controlled drug half of this question is settled and the product half is not. Amanita muscaria is...
Amyl Nitrite	Not confirmed. Amyl nitrite is not named in Annexes I to IV of the Royal Decree of 6 September 2017, so the...
Phenibut	Not confirmed. Phenibut, also written fenibut and described as beta-phenyl-GABA, is not named in Annexes I to IV of...
Scopolamine (Devil's Breath)	Not confirmed. Scopolamine, also called hyoscine, is not named in Annexes I to IV of the Royal Decree of 6 September...
Xylazine	Not confirmed. Xylazine is not named in Annexes I to IV of the Royal Decree of 6 September 2017, so it is not a...

Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.

Before you travel

Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.

If you’re detained or arrested abroad

Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →

← All countries Drug index